Standard BioTools Net Tangible Assets

Standard BioTools posts a net tangible assets of $560M as of March 2026. That compares with $450M in the prior-year period — up 23.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Standard BioTools's net tangible assets was $450M. The latest reading is $560M — a 23.4% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Net Tangible Assets is one piece of Standard BioTools's financial statement story. At $560M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LAB's net tangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Standard BioTools's other metric pages and overview cover the third.

Judging Standard BioTools against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in net tangible assets easier to interpret. Start with $560M here, then scan peer and history charts to see if the gap is persistent.